Ahuva Averin
5PUBLICATIONS
13CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jan 21, 2026
Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.Diana Mendes, Ahuva Averin, Mark Atwood
|Jun 04, 2025
Cost-effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine in Indian adults aged ≥50 years.Namrata Kulkarni, Ahuva Averin, Santosh Taur
|May 03, 2024
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.Lucila Rey-Ares, Ahuva Averin, Mercedes Mac Mullen
|Oct 13, 2022
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.Diana Mendes, Ahuva Averin, Mark Atwood
|Aug 05, 2022
Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England.Tendai Mugwagwa, Ahuva Averin, Mark Atwood
Pageof 1
Frequent Collaborators
3 joint publications
Tendai Mugwagwa
3 joint publications
Reiko Sato
3 joint publications
Andrew Vyse
3 joint publications
James Campling
3 joint publications
Derek Weycker
3 joint publications
Diana Mendes
3 joint publications
Dhwani Hariharan
2 joint publications
Mary Slack
2 joint publications
Gillian Ellsbury
1 joint publications
Lucila Rey-Ares
